Surgery: 2,208 Real Stories

2,208 stories match surgery. 1,436 of them mention chemotherapy.

Cancer Stories

A patient, who was diagnosed with Stage III Colorectal AdenocarcinomaColorectal Cancer

Teenage colorectal cancer: Stage III signet-ring adenocarcinoma and 10-year disease-free follow-up after FOLFOX

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: CDX2-positive; CK7-positive; AE1-AE3-positive; signet-ring cell adenocarcinoma histology

As of November 2025, she was disease-free 10 years after laparoscopic right hemicolectomy with clear margins and 6 months of adjuvant FOLFOX for T4N2Mx signet-ring colon adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Breast AdenocarcinomaBreast Cancer

Synchronous EGFR-mutated lung adenocarcinoma and metastatic breast cancer: surgery and adjuvant therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Two cancers: lung adenocarcinoma with EGFR exon 19 deletion; breast cancer ER-positive, PR-low, HER2 non-amplified.

Metastatic Site: lung

Follow-up CT on 26 December 2024 showed no recurrence, with disease-free survival estimated at 27 months to 1 April 2025 while on icotinib and letrozole maintenance.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Ovarian CancerOvarian Cancer

Stage I Immature Ovarian Teratoma With a Benign Teratoma in the Other Ovary

Patient Info: Anonymized, female, Under 40 | Stage I

Biomarkers: AFP 90 ng/mL at diagnosis; CA-125 within normal range

Follow-up imaging showed no recurrence, and she remained well under regular oncologic surveillance after chemotherapy was stopped early.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Colorectal CancerColorectal Cancer

Colon cancer patient with insulin autoimmune syndrome after FOLFOX, bevacizumab, and omeprazole

Patient Info: Anonymized, Male, 70+

Biomarkers: No cancer biomarkers reported. Insulin autoimmune syndrome followed chemotherapy/omeprazole exposure.

As of November 2025, the rare insulin autoimmune syndrome episode had improved after glucose supplementation and prednisone acetate, with blood glucose returning to the normal range during postoperative colon cancer treatment.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple-negative breast cancer with pathologic complete response after neoadjuvant chemoimmunotherapy complicated by immune toxicity

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative

Left mastectomy on November 17 confirmed pathologic complete response, and 5-month follow-up showed no residual hepatic, dermatological, metabolic, or neurological sequelae from the treatment-related complications.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Lung AdenocarcinomaLung Cancer

Stage IA1 lung adenocarcinoma: disease-free after VATS right lower lobectomy

Patient Info: Anonymized, Male, 70+

Biomarkers: No molecular biomarkers reported; final pathology pT1aN0M0 with no lymph node metastases

Final pathology showed pT1aN0M0 Stage IA1 lung adenocarcinoma with no lymph node metastases, and he remained disease-free at 1-year follow-up.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Breast CancerBreast Cancer

Breast cancer history with severe MSSA infective endocarditis and vascular complications

Patient Info: Anonymized, Female

Her breast cancer treatment was historical; the active episode was MSSA infective endocarditis with embolic complications, treated successfully with antibiotics, hepatic artery embolization, and aortic valve replacement, followed by asymptomatic 3-month outpatient review.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage 0 Invasive Ductal CarcinomaBreast Cancer

HER2-positive DCIS with KLHL11 encephalitis and pulmonary adenocarcinoma in situ

Patient Info: Anonymized, Female, Under 40 | Stage 0

Biomarkers: Breast DCIS was ER/PR positive and HER2 positive

After local breast treatment and later lung resection, she was asymptomatic on levetiracetam and tamoxifen, with no recurrent fever, seizures, or ataxia reported.

PubMed Central
OutcomeSurvivorship / Completed Treatment
Michelle, who was diagnosed with Non-Small Cell Lung CancerLung Cancer

EGFR Non-Small Cell Lung Cancer: Michelle's Patient Story

Patient Info: Michelle Vacca, Female, 40s

Biomarkers: EGFR mutation at recurrence; later rare mutation not named

As of November 2025, Michelle still actively had recurrent NSCLC, but her disease had remained stable on targeted therapy and an investigational kinase inhibitor clinical trial, allowing good quality of life.

City of Hope
OutcomeLiving With Cancer
Stacy, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III Invasive Lobular Carcinoma: Stacy's Survivor Story

Patient Info: Stacy, Female | Stage III

Biomarkers: Hormone receptor-positive; HER2-negative

Stacy completed chemotherapy, mastectomy, radiation and reconstruction. She remained under regular monitoring and was taking Letrozole as part of a planned 10-year course.

Lobular Breast Cancer Alliance
OutcomeCare Ongoing / Survivorship
A patient, who was diagnosed with Stage I Lung AdenocarcinomaLung Cancer

Second primary Stage I lung adenocarcinoma treated with segmentectomy and adjuvant pembrolizumab

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: PD-L1 <1%; no common targetable lung cancer changes found in EGFR, ALK, KRAS, BRAF, MET, PIK3CA, RET, ROS1, or NTRK.

At 6-month oncologic follow-up, PET-CT showed complete metabolic response with no evidence of residual disease after segmentectomy and adjuvant pembrolizumab.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV KRAS-mutant colorectal cancer with bilobar liver metastases: multimodality treatment and no evidence of disease

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: KRAS-mutated; BRAF wild-type; mismatch repair proficient

Metastatic Site: liver

After second liver resection, follow-up MRI at 8 weeks showed continued response at the SABR site and no recurrent disease; she was receiving adjuvant capecitabine and remained well.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIB RET-fusion lung adenocarcinoma: disease-free after pralsetinib, surgery and maintenance therapy

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: RET exon 12 fusion. Lung-origin markers were present

After neoadjuvant pralsetinib, surgery showed pathological complete response with negative lymph nodes. As of 16 April 2025, surveillance imaging showed no recurrence while he remained on pralsetinib 300 mg once daily.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage IIIB HER2-positive breast cancer followed by resected pancreatic ductal adenocarcinoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Breast cancer HER2-amplified; ER/PR changed from positive to negative after treatment. Pancreatic markers supported a separate pancreatic cancer.

The breast cancer achieved radiological and clinical remission after multimodality HER2-directed treatment. In 2025, a separate pancreatic ductal adenocarcinoma was resected, and adjuvant gemcitabine plus albumin-bound paclitaxel was recommended.

PubMed Central
OutcomeCare Ongoing
Janella, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Janella's Survivor Story

Patient Info: Janella Bustamante, Female, 40s

Biomarkers: Triple-positive: estrogen-, progesterone- and HER2-fueled breast cancer

As of October 2025, Janella had completed lumpectomy, chemotherapy, radiation and HER2-targeted biological therapy for triple-positive breast cancer and was on follow-up every 3 months; the source describes life after cancer but does not explicitly state NED/cancer-free.

Cleveland Clinic
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Metastasizing ameloblastoma involving lung Squamous Cell CarcinomaMetastasizing ameloblastoma involving lung

Metastasizing ameloblastoma involving lung: initially treated as squamous lung cancer

Patient Info: Anonymized, Male, 40s

Biomarkers: Final tumor had AKT1 mutation and BRAF -negative status. Initial testing found no common actionable lung-cancer drivers.

As of October 2025, final pathology had changed the diagnosis from suspected squamous lung cancer to metastasizing ameloblastoma involving the lung, and the patient was under specialist head-and-neck and thoracic follow-up.

PubMed Central
OutcomeCare Ongoing
Nicole, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Triple-Negative Breast Cancer: Nicole's Patient Story

Patient Info: Nicole, Female, 40s | Stage IV

Biomarkers: ER-negative; PR-negative; HER2-negative

Metastatic Site: liver

Nicole remained in active treatment for liver-metastatic triple-negative breast cancer, with meaningful response after switching to an antibody-drug conjugate and then undergoing mastectomy.

The Patient Story
OutcomeResponding Well